Pfizer immuno-oncology drug wins U.S. approval for bladder cancer

(Reuters) - U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno-oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA.Bavencio, known chemically as avelumab, was approved for patients with locally advanced or metastatic bladder cancer whose disease progressed during or following platinum-containing chemotherapy or within 12 months of chemotherapy t